The pharmaceutical firm has agreed to supply $50m in cash and services to small-molecule drug developer Dice Molecules as part of a collaboration agreement.
Pharmaceutical company Sanofi agreed yesterday to provide “in excess of” $50m in equity funding, fees and research services for US-based small-molecule drug development startup Dice Molecules.
Dice is developing small-molecule compounds that could potentially unlock protein-protein interfaces that orally-taken drugs have found intractable. It aims to fund its work chiefly through revenues and milestone awards gained through collaborations.
The cash and services, as well as upfront, target exclusivity and technology access fees, will be supplied to Dice as part of…
